The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is a huge mover today! About 1.19M shares traded hands or 140.46% up from the average. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has risen 50.97% since April 18, 2016 and is uptrending. It has outperformed by 46.54% the S&P500.
The move comes after 6 months negative chart setup for the $2.96 billion company. It was reported on Nov, 18 by Barchart.com. We have $108.31 PT which if reached, will make NASDAQ:GWPH worth $236.80M less.
Analysts await GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to report earnings on December, 5. They expect $-1.59 earnings per share, down 87.06% or $0.74 from last year’s $-0.85 per share. After $-0.73 actual earnings per share reported by GW Pharmaceuticals PLC- ADR for the previous quarter, Wall Street now forecasts 117.81% negative EPS growth.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Ratings Coverage
Out of 8 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. GW Pharmaceuticals has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Goldman Sachs initiated the shares of GWPH in a report on Friday, October 7 with “Buy” rating. The company was initiated on Monday, June 27 by Janney Capital. The firm has “Overweight” rating given on Thursday, August 13 by Morgan Stanley. Cantor Fitzgerald maintained it with “Buy” rating and $182 target price in Monday, September 26 report. As per Monday, November 30, the company rating was initiated by TH Capital. On Friday, August 26 the stock rating was upgraded by Numis Securities to “Hold”. Roth Capital maintained GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Monday, March 14 with “Buy” rating. The stock has “Buy” rating given by Cantor Fitzgerald on Friday, June 3. Roth Capital initiated GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Monday, November 30 with “Buy” rating.
According to Zacks Investment Research, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.”
More notable recent GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) news were published by: Investorplace.com which released: “GW Pharmaceuticals (GWPH) Stock Landed a 1-2 Ballot Punch” on November 11, 2016, also Marketwatch.com with their article: “GW Pharmaceuticals PLC ADR” published on May 08, 2013, Investorplace.com published: “GW Pharmaceuticals PLC- ADR Is a First-Rate Marijuana Stock (GWPH)” on September 26, 2016. More interesting news about GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) were released by: Investorplace.com and their article: “GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill” published on September 07, 2016 as well as Investorplace.com‘s news article titled: “GW Pharmaceuticals PLC-ADR: Why GWPH Is Set to Burn Higher” with publication date: June 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.